Novo is the anti-Genentech: it has built its business with incremental innovation and a phenomenal focus on its insulin customer. The firm is now hoping to duplicate its insulin success with another diabetes product capable of sustaining a set of variations and delivery alternatives.
About
EPT Useful Links
- BioHealth Investor
- Drug Discovery Today
- EuroPharma Today
- Eye on FDA
- FDA Law Blog
- IN VIVO
- The IN VIVO Blog
- Inteleos
- Medical Devices Today
- OverTheCounterToday
- Pharmalot
- PharmaAsia News
- RPM Report
- Search Company Profiles
- SPICY IP Blog (India)
- Start-Up
- The Gold Sheet
- The Pink Sheet
- The Pink Sheet DAILY
- The Tan Sheet
Notices
- Copyright© 2012, F-D-C Reports, Inc. and Windhover Information Inc. All rights reserved.
Search EPT
Featured Events
- Euro-Biotech Partnering Summit
May 30 - June 1, 2012 Hilton Arc de Triomphe Paris - Pharmaceutical Strategic Outlook
April 11-13, 2012 Grand Hyatt New York, NY - Wharton/Windhover Program
May 14, 2012 - May 18, 2012 Philadelphia, PA
